- NEWS
Omicron-targeted vaccines do no better than original jabs in early tests
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-022-00003-y
References
Gagne, M. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?s=08 (2022).
Ying, B. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.07.479419v1 (2022).
Lee, I.-J. et al. Preprint at bioRixv https://www.biorxiv.org/content/10.1101/2022.01.31.478406v1 (2022).
Hawman, D. W. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.01.31.478520v1 (2022).